SG11202012360YA - Anti-il36r antibodies - Google Patents

Anti-il36r antibodies

Info

Publication number
SG11202012360YA
SG11202012360YA SG11202012360YA SG11202012360YA SG11202012360YA SG 11202012360Y A SG11202012360Y A SG 11202012360YA SG 11202012360Y A SG11202012360Y A SG 11202012360YA SG 11202012360Y A SG11202012360Y A SG 11202012360YA SG 11202012360Y A SG11202012360Y A SG 11202012360YA
Authority
SG
Singapore
Prior art keywords
il36r antibodies
il36r
antibodies
Prior art date
Application number
SG11202012360YA
Other languages
English (en)
Inventor
Jeanette Fairhurst
Elena Garnova
William Olson
Sokol Haxhinasto
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202012360YA publication Critical patent/SG11202012360YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202012360YA 2018-07-16 2019-07-16 Anti-il36r antibodies SG11202012360YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862698482P 2018-07-16 2018-07-16
US201962846989P 2019-05-13 2019-05-13
US201962866028P 2019-06-25 2019-06-25
PCT/US2019/041952 WO2020018503A2 (fr) 2018-07-16 2019-07-16 Anticorps anti-il36r

Publications (1)

Publication Number Publication Date
SG11202012360YA true SG11202012360YA (en) 2021-01-28

Family

ID=67480435

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012360YA SG11202012360YA (en) 2018-07-16 2019-07-16 Anti-il36r antibodies

Country Status (13)

Country Link
US (1) US11267893B2 (fr)
EP (1) EP3823989A2 (fr)
JP (1) JP7386224B2 (fr)
KR (1) KR20210032401A (fr)
CN (1) CN112513091A (fr)
AU (1) AU2019306217B2 (fr)
BR (1) BR112020027015A2 (fr)
CA (1) CA3103531A1 (fr)
IL (1) IL280013A (fr)
MX (1) MX2021000566A (fr)
PH (1) PH12020552178A1 (fr)
SG (1) SG11202012360YA (fr)
WO (1) WO2020018503A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
WO2022026829A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) pour traiter la toxicité cutanée
EP4188441A1 (fr) 2020-07-30 2023-06-07 AnaptysBio, Inc. Thérapie contre l'ichtyose à anti-récepteur de l'interleukine 36 (il-36r)
CN116685605A (zh) * 2020-12-17 2023-09-01 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022150644A1 (fr) 2021-01-08 2022-07-14 Anaptysbio, Inc. Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r)
WO2022150642A1 (fr) 2021-01-08 2022-07-14 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) contre la maladie de verneuil
WO2022166977A1 (fr) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 Anticorps anti-il-36r humain et son application
CA3209006A1 (fr) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Procedes de traitement du ppg
WO2022192531A2 (fr) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarqueurs associés au traitement par anticorps anti-il-36 r dans le psoriasis pustuleux généralisé
KR20240022546A (ko) * 2021-06-18 2024-02-20 치아타이 티안큉 파마수티컬 그룹 주식회사 항il-36r 항체 및 그의 사용
WO2023285362A1 (fr) * 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs d'il-36 permettant le traitement du syndrome de netherton
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
AU705595B2 (en) 1994-09-09 1999-05-27 Neurocrine Biosciences, Incorporated Interleukin-1 type 3 receptors
US6239268B1 (en) 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
WO1999019480A2 (fr) 1997-10-15 1999-04-22 Schering Corporation Proteines receptrices humaines et reactifs et methodes associes
US20060003323A1 (en) 2000-03-01 2006-01-05 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030170630A1 (en) 2000-12-21 2003-09-11 Alsobrook John P. Proteins and nucleic acids encoding same
WO2005097421A2 (fr) 2004-04-01 2005-10-20 Sequenom, Inc. Procedes d'identification de risque d'osteoarthrite et traitements correspondants
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
EP1938104A2 (fr) 2005-10-17 2008-07-02 Institute for Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
DK2780373T3 (da) * 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP3404116B1 (fr) * 2013-03-15 2022-10-19 The University of Chicago Procédés et compositions liés à l'activité des lymphocytes t
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
WO2018183173A1 (fr) 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Polythérapie à base d'anticorps anti il-36r

Also Published As

Publication number Publication date
IL280013A (en) 2021-03-01
MX2021000566A (es) 2021-06-23
KR20210032401A (ko) 2021-03-24
AU2019306217B2 (en) 2024-01-25
JP7386224B2 (ja) 2023-11-24
US11267893B2 (en) 2022-03-08
JP2021530229A (ja) 2021-11-11
WO2020018503A3 (fr) 2020-02-20
CA3103531A1 (fr) 2020-01-23
AU2019306217A1 (en) 2021-01-14
WO2020018503A2 (fr) 2020-01-23
US20200017592A1 (en) 2020-01-16
BR112020027015A2 (pt) 2021-04-06
CN112513091A (zh) 2021-03-16
EP3823989A2 (fr) 2021-05-26
PH12020552178A1 (en) 2021-06-28

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-TIGIT antibodies
IL279352A (en) IL-11RA antibodies
GB201709808D0 (en) Antibodies
IL280013A (en) Anti-IL36R antibodies
IL278010A (en) Antibodies to galectin 10
IL289112A (en) Antibodies against tigit
IL277030A (en) Antibodies
GB201707561D0 (en) GARP-TGF-beta antibodies
SG11202106171WA (en) Anti-btla antibodies
IL291068A (en) Anti-cd73 antibodies
ZA202101177B (en) Anti-btla antibody
IL284584A (en) Anti-tigit antibodies
GB201811368D0 (en) Antibody
IL281594A (en) Antibodies against KLRG1
GB201817172D0 (en) Antibody
GB201905150D0 (en) Ant-ige antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB201711785D0 (en) Antibodies
SG11202105718TA (en) Modified antibodies
GB201819952D0 (en) Antibodies